TB-500What the studies show

The study most often quoted is from 1999. Researchers at the U.S. National Institutes of Health made full-thickness wounds on the backs of rats and gave thymosin beta-4 either applied to the wound or injected into the abdomen. Treated wounds closed faster than wounds given a control solution, with more collagen laid down and more new blood vessels in the wound bed ². In the same paper, the protein made cultured keratinocytes — the cells that resurface a wound — migrate faster, which fits a molecule whose job is to free up actin ².

In 2004 a group at the University of Texas Southwestern tied off a coronary artery in mice to mimic a heart attack and then injected thymosin beta-4. Treated mice had better pumping function on ultrasound and smaller scars in the weeks that followed, and heart muscle cells grown with the protein survived low-oxygen conditions better. The authors traced the effect to integrin-linked kinase, a signal that helps cells survive and move ³. A mouse heart is not a human heart, but this paper is the reason thymosin beta-4 is taken seriously as a repair molecule and not only as a wound dressing.

Why study a fragment instead of the protein? In 2003 the NIH group asked which part of thymosin beta-4 does the work. They synthesised the short actin-binding stretch, the sequence LKKTET, and tested it alone. In a dish the fragment made endothelial cells — the cells that line blood vessels — attach and migrate, and in rings of rat aorta it drove the sprouting of new vessels, much as the full protein did ¹. That is the best evidence that the piece keeps some of the parent's activity. It is also most of what exists: the wound and heart studies above used the whole protein, and the fragment has not been put through the same animal tests.

Thymosin beta-4 itself, as the full protein, has been through early human trials, mostly for the eye. In a 2015 randomized trial, 72 people with severe dry eye received either 0.1% thymosin beta-4 eye drops or placebo drops for 28 days; the treated group had less damage to the corneal surface and reported less discomfort ⁴. A separate study gave healthy volunteers thymosin beta-4 by intravenous infusion, as single doses and then daily for 14 days, to see how the body handled it; the authors reported no serious adverse events, and the protein left the blood quickly ⁵. These were small trials of the whole protein, and none looked at tendons, muscles or joints.

One more fact worth knowing: the World Anti-Doping Agency lists thymosin beta-4 and its derivatives, naming TB-500 specifically, among the substances banned in sport at all times ⁶.